Latest abdominal aortic aneurysm Stories
Y chromosome linked to fatal aneurysmResearch currently being undertaken at the University of Leicester may identify reasons underlying an increased risk of Abdominal Aortic Aneurysms (AAA) in men.In her doctoral study, Cardiovascular Sciences student Lisa Bloomer is looking into the causes of the male predominance of AAA, with a particular emphasis on genetic basis of the disease. Preliminary results from the study will be showcased at the University of Leicester's Festival of Postgraduate...
IRVINE, Calif., June 10 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its expanded offering of Powerlink® stent graft products. The approval covers 31 new sizes of Powerlink® main body bifurcated, proximal extension, and limb extension stent grafts that increase the system's addressable patient population by 5% to 10%....
BOSTON, June 7 /PRNewswire/ -- Patients with abdominal aortic aneurysms (AAAs) of less than 5.5 cm have no significant differences in clinical outcomes after endovascular repair (EVAR) than those with larger AAAs according to data from a five-year prospective clinical trial setting. The researchers maintain their recommendation that small aneurysms should not be treated surgically. Details of this study were presented at the 64th Vascular Annual Meeting presented by the Society for Vascular...
IRVINE, Calif., June 4 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that TechAmerica has named Endologix as Orange County's Outstanding Company in Medical Technology. The award was presented to Endologix at the 17th Annual TechAmerica High-Tech Innovation Awards on June 2, 2010 in Irvine, CA. John McDermott, President and CEO, said, "It is an honor to receive this award from TechAmerica. It is a...
IRVINE, Calif., June 1 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the Jefferies 2010 Global Life Sciences Conference in New York, NY. Jefferies 2010 Global Life Sciences Event: Conference Date: Wednesday, June 9, 2010 Time:...
IRVINE, Calif., May 21 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that Thomas C. Wilder has joined the Endologix Board of Directors. Mr. Wilder was elected to the Board during the Company's 2010 Annual Meeting of Stockholders held on May 20, 2010. He replaces Paul McCormick, whose term on the Board expired at the Annual Meeting. With the addition of Mr. Wilder and the departure of Mr. McCormick,...
CHICAGO, May 19 /PRNewswire/ -- Preoperative statin therapy has a protective effect on patients undergoing elective abdominal aortic aneurysm (AAA) repair that reduces risk and subsequent total hospital costs according to a new study from researchers at the East Carolina Heart Institute in Greenville, North Carolina. Published in the June issue of the Society of Vascular Surgery's®, Journal of Vascular Surgery®, this retrospective review compares 401 patients who underwent an elective...
BOSTON, May 17 /PRNewswire/ -- The vascular surgeons at Massachusetts General Hospital (MGH) in Boston have traditionally repaired thoracoabdominal aortic aneurysms (TAA) with a clamp and sew (CS) technique that includes neuro-protective adjuncts like epidural cooling and aggressive intercostal reconstruction (IC) to prevent spinal cord ischemia. The last five years have seen a paradigm shift to distal aortic perfusion (DAP) during aortic cross clamping with the concurrent use of motor...
Peripheral Vascular Device Market to Almost Double by 2016 VANCOUVER, May 11 /PRNewswire-FirstCall/ - According to a new report by iData Research (www.idataresearch.net), the leading authority in medical device and pharmaceutical market research, the U.S. peripheral vascular device market is worth $2.8 billion with expected growth to over $5.3 billion by 2016. Increased detection and treatment of abdominal aortic aneurysms (AAAs) and peripheral arterial disease (PAD) are the main drivers...
IRVINE, Calif., April 28 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the publication of consolidated results from its prospective, multicenter clinical trials of the Company's Powerlink® stent graft for the endovascular repair of abdominal aortic aneurysms (AAA) using an anatomical fixation technique. The trial results demonstrate no aneurysm ruptures, no conversions to open repair, no device...
